Lyell Immunopharma (NASDAQ:LYEL) Reaches New 1-Year Low - Here's Why

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $0.40 and last traded at $9.73, with a volume of 865368 shares changing hands. The stock had previously closed at $0.40.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "neutral" rating and set a $20.00 price target on shares of Lyell Immunopharma in a report on Wednesday, April 16th.

Lyell Immunopharma Trading Down 11.6%

The firm has a market capitalization of $176.29 million, a price-to-earnings ratio of -15.07 and a beta of -0.26. The company has a fifty day moving average price of $8.80 and a 200-day moving average price of $11.97.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($3.60) earnings per share for the quarter, topping the consensus estimate of ($3.80) by $0.20. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The firm had revenue of $0.01 million during the quarter. As a group, sell-side analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Insider Buying and Selling

In other Lyell Immunopharma news, CEO Lynn Seely purchased 8,750 shares of the business's stock in a transaction dated Friday, March 14th. The stock was bought at an average cost of $12.20 per share, for a total transaction of $106,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 35,625 shares in the company, valued at $434,625. This represents a 32.56% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sumant Ramachandra purchased 10,000 shares of the business's stock in a transaction dated Friday, March 21st. The shares were acquired at an average price of $11.60 per share, with a total value of $116,000.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company's stock, valued at approximately $116,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 38,432 shares of company stock worth $449,508. 25.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Decheng Capital LLC acquired a new position in shares of Lyell Immunopharma during the fourth quarter worth approximately $7,622,000. Foresite Capital Management V LLC acquired a new position in shares of Lyell Immunopharma during the fourth quarter worth approximately $5,205,000. venBio Partners LLC acquired a new position in shares of Lyell Immunopharma during the fourth quarter worth approximately $4,545,000. Geode Capital Management LLC lifted its holdings in shares of Lyell Immunopharma by 2.9% during the fourth quarter. Geode Capital Management LLC now owns 4,137,264 shares of the company's stock worth $2,648,000 after buying an additional 117,303 shares during the last quarter. Finally, Almitas Capital LLC lifted its holdings in shares of Lyell Immunopharma by 136.3% during the first quarter. Almitas Capital LLC now owns 2,482,606 shares of the company's stock worth $1,336,000 after buying an additional 1,432,086 shares during the last quarter. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.